Previous studies showed indeed that FLT3-driven acute myeloid leukemia (AML) cells exposed to FLT3 inhibitors together with the inhibition of the ATM/G6PDH axis showed a higher response to therapy [25]. This evidence concerns the gene FLT3 and acute myeloid leukemia.